This finding may add another possible mechanism through which SGK1 inhibition might be beneficial in hepatocarcinoma treatment; indeed, NDRG1 has been proposed as a potential therapeutic target for HCC [29]. This evidence concerns the gene NDRG1 and hepatocellular carcinoma.